Renalytix Plc

BST:2O9A Stock Report

Market Cap: €41.5m

Renalytix Management

Management criteria checks 1/4

Renalytix's CEO is James McCullough, appointed in Mar 2018, has a tenure of 6.17 years. total yearly compensation is $1.04M, comprised of 58% salary and 42% bonuses, including company stock and options. directly owns 1.78% of the company’s shares, worth €738.19K. The average tenure of the management team and the board of directors is 6.2 years and 0.8 years respectively.

Key information

James McCullough

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage58.0%
CEO tenure6.2yrs
CEO ownership1.8%
Management average tenure6.2yrs
Board average tenureless than a year

Recent management updates

Recent updates

CEO Compensation Analysis

How has James McCullough's remuneration changed compared to Renalytix's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$37m

Dec 31 2023n/an/a

-US$42m

Sep 30 2023n/an/a

-US$44m

Jun 30 2023US$1mUS$601k

-US$46m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022n/an/a

-US$42m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022US$636kUS$601k

-US$45m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021n/an/a

-US$44m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021US$1mUS$586k

-US$35m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020US$488kUS$470k

-US$10m

Mar 31 2020n/an/a

US$28m

Dec 31 2019n/an/a

-US$8m

Sep 30 2019n/an/a

-US$5m

Jun 30 2019US$216kUS$269k

-US$42m

Compensation vs Market: James's total compensation ($USD1.04M) is above average for companies of similar size in the German market ($USD384.00K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

CEO

James McCullough (55 yo)

6.2yrs

Tenure

US$1,036,321

Compensation

Mr. James R. McCullough, M.B.A. is Co-Founder and has been the Chief Executive Officer of Renalytix Plc (formerly, Renalytix AI plc) since March 15, 2018 and served as its Executive Director. Mr. McCulloug...

Leadership Team

NamePositionTenureCompensationOwnership
James McCullough
Chief Executive Officer6.2yrsUS$1.04m1.78%
€ 738.2k
Oliver Sterling
Chief Financial Officer6.2yrsUS$623.68k1.17%
€ 485.2k
Fergus Fleming
Chief Technology Officer6.2yrsno data0.37%
€ 153.1k
Howard Doran
Presidentless than a yearno datano data
Salim Hamir
Company Secretaryno datano datano data

6.2yrs

Average Tenure

55yo

Average Age

Experienced Management: 2O9A's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Levangie
Independent Non-Executive Director2.8yrsUS$24.00k0%
€ 0
Erik Lium
Independent Non-Executive Director5.5yrsUS$24.00kno data
Christopher Mills
Independent Non-Executive Chairman6.2yrsUS$24.00k6.52%
€ 2.7m
Stephen Brunton
Member of Clinical Advisory Boardless than a yearno datano data
Matthew Budoff
Member of Clinical Advisory Boardless than a yearno datano data
Ralph Defronzo
Member of Clinical Advisory Boardless than a yearno datano data
Barry Freedman
Member of Clinical Advisory Boardno datano datano data
Joseph Vassalotti
Member of Clinical Advisory Board4.8yrsno datano data
Catherine Coste
Independent Non-Executive Directorless than a yearno data0%
€ 0
Holly Mattix-Kramer
Member of Clinical Advisory Boardless than a yearno datano data
Javier Morales
Member of Clinical Advisory Boardless than a yearno datano data
Eugene Wright
Member of Clinical Advisory Boardless than a yearno datano data

0.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 2O9A's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/18 09:48
End of Day Share Price 2024/02/20 00:00
Earnings2024/03/31
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Renalytix Plc is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Mark MassaroBTIG
David WestenbergGuggenheim Securities, LLC